Growth Hormone Controls Sex Differences in Liver Disease Risk Through Gene Switches

This groundbreaking research explains why men and women face different risks for liver diseases and metabolic disorders, opening doors to sex-specific treatments that could significantly impact healthspan and longevity.

Scientists at Boston University investigated how growth hormone creates sex-specific genetic control switches in liver cells. They developed an innovative technique called HDI-STARR-seq, testing nearly 24,000 genetic regulatory sequences delivered directly to mouse livers to identify which ones respond to growth hormone differently in males versus females.

The researchers discovered 840 functional genetic switches that control liver metabolism in sex-specific ways. These switches regulate genes responsible for fat processing, bile acid synthesis, and toxin removal - all critical functions that decline with age and contribute to metabolic diseases. The switches contain binding sites for specific proteins including STAT5, BCL6, and CUX2 that act as molecular gatekeepers.

Most importantly, these sex-biased switches control both disease-promoting and disease-protective genes linked to fatty liver disease (MASLD). This discovery helps explain why women typically have lower rates of fatty liver disease before menopause, while men show earlier susceptibility to metabolic liver disorders.

For longevity and health optimization, this research suggests that hormone-based interventions and metabolic therapies should be tailored by biological sex. The identified genetic switches could become targets for personalized treatments that work with, rather than against, natural sex differences in metabolism. However, this was conducted in mice, and human validation is needed before clinical applications can be developed.